Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TOP-RA trial
2025-524593-42-00Phase 4Authorised
- Sponsor
- Leiden University
- Start
- Oct 2026
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of abatacept, adalimumab, certolizumab pegol, etanercept, infliximab and 2 more in rheumatoid arthritis (RA) (3 arms), sponsored by Leiden University. Primary endpoint: Successful tapering probability at 9 months. Planned start Oct 2026; status: authorised.
02
Drugs
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2025-524593-42-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-524593-42-00.